Gilead Acquires Arcellx in $7.8 Billion Deal to Advance Cancer Therapies
Gilead Sciences is set to acquire Arcellx in a deal valued at $7.8 billion, bolstering its oncology pipeline with a promising CAR T-cell therapy for multiple myeloma. The acquisition, announced on Monday, aims to fast-track the development and commercialization of anitocabtagene autoleucel (anito-cel), a potential breakthrough treatment for patients with relapsed or refractory multiple myeloma.
Deal Details and Financials
Under the terms of the agreement, Gilead will pay $115 per share in cash, plus a contingent value right of $5 per share. Gilead already holds approximately 11.5% of Arcellx’s outstanding common stock. The acquisition is expected to accelerate the path to market for anito-cel, eliminating profit-sharing and royalties associated with their previous collaboration Newsbreak.
Anito-cel: A Promising Therapy for Multiple Myeloma
Anito-cel is a CAR T-cell therapy currently under review by the Food and Drug Administration (FDA). The Biologics License Application (BLA) is being evaluated for use as a fourth-line treatment for multiple myeloma patients who have exhausted other options. The FDA is expected to make a decision by December 23, 2026 Newsbreak.
Preliminary results from the Phase 2 iMMagine-1 study have demonstrated deep and durable responses with a predictable and manageable safety profile. Arcellx presented late-breaking data at TANDEM, highlighting the unique, high target-specificity of anito-cel’s D-Domain binder Arcellx.
Arcellx’s Technology and Pipeline
Arcellx focuses on reimagining cell therapy through its D-Domain technology and ARC-SparX platforms. The company aims to “supercharge how the world treats cancer” Arcellx. Beyond anito-cel, Arcellx continues to develop its broader pipeline and research novel product candidates.
Gilead’s Strategic Move
“This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences Newsbreak.
The acquisition of Arcellx aligns with Gilead’s long-term oncology strategy and strengthens its position in the competitive CAR T-cell therapy market.